Oncology

We collaborate closely with our clients

to build a healthier future.

Comprehensive Oncology Solutions

At QIMA Life Sciences, we provide a wide range of oncology-focused solutions to support drug discovery and development. From mechanistic in vitro assays to advanced in vivo oncology models (in partnership with our partner Axis Bio), we deliver reliable and scientifically robust studies to accelerate your program.

Our oncology capabilities cover multiple cancer types, including both solid tumors (breast, colon, glioblastoma, lung, liver, bladder, prostate, head and neck, pancreatic, melanoma) and hematologic malignancies (leukemia, lymphoma) and more).

Cancer cell line portfolio:

QIMA Life Sciences maintains a cell bank of more than 130 well-characterized cancer cell lines, enabling a broad spectrum of oncology research.

  • Hematologic cancers: leukemia, lymphoma,
  • Solid tumors: breast, colon, liver, lung, bladder, prostate, head and neck…

In addition to our in-house cell line portfolio, Axis Bio supports validation of client-specific cell lines and implantation in both flank and orthotopic sites, expanding the scope of tumor models available for oncology research.

Discover our blog articles

How Inflammation Can Spark and Fuel Cancer

In Vitro Assays to Study The Hallmarks of Cancer

Cancer TypeCell lines
BladderRT112, 647-V, VM-CUB-2, J82, RT4, UMUC-6
BrainU87-MG, U251-MG, KELLY
BreastHCC38, JIMT-1, KLP-4, MDA-MB-157, MDA-MB-231, MDA-MB-468, MCF-7, SKBR3, T47D, ZR-75-1
BoneSaos-2, U-2 OS
ColorectalDLD-1, SW48, HT29, HCT116, SW620, SNU-1411
FibrosarcomaHT1080
GastricNCI-N87
HepaticHepG2
LeukaemiaCCRF-HSB2, HL-60, MOLT-4, Jurkat, NOMO-1, THP-1, K562, MOLM-13, HNT-34
Lung (NSCLC)A427, A549, H2122, PC9
LymphomaOCI-Ly10, TMD8, Raji, Ramos
MelanomaA375
MyelomaMM.1S, RPMI8226
OvarianSKOV3, OVCAR3, OVCAR4, IGROV-1, TOV112D
PancreaticAsPC-1, BxPC3, Capan-1, HPAFII, MIA PaCa-2, Panc1
Prostate22rv1, C4-2, LNCaP, DU145, PC3, VCaP
RenalA498, 786-0, ACHN

In vitro Oncology Assays

Our in vitro platforms allow detailed evaluation of compound efficacy and mechanism of action across the hallmarks of cancer.

Cytotoxicity profiling

  • LDH release
  • MTT reduction
  • Annexin V / PI
  • High content assay

Cell proliferation

  • [3H]-Thymidine incorporation
  • BrdU incorporation
  • Ki-67-labeling


Signal transduction

  • Protein phosphorylation and localization
  • Signal transduction pathways
  • DNA damage (H2A.X, 8-OH-dG)

Vascularization assessment

  • VEGF release
  • Adhesion proteins expression
  • Cell tube formation

Cell migration & invasion

Biomarker identification & validation

Through our partnership with Axis Bio, we also offer post-study analyses such as histology, real-time PCR, blood counts, and clinical chemistry to provide deeper mechanistic insights.

Discover our
oncology-related assays

Tumor Microenvironment (TME) & Immuno-Oncology Assays

Understanding the interaction between tumors and immune cells is critical for oncology drug discovery. QIMA Life Sciences offers assays covering a wide range of immune cell types:

Immune cells:

  • Neutrophils, basophils, eosinophils
  • Monocytes, macrophages, dendritic cells
  • T cells and regulatory T cells








Assays:

  • PMN, Macrophage, Dendritic Cell activation
  • Phagocytosis
  • PMN oxidative burst
  • M1 or M2 polarization and switch
  • Chemotaxis
  • T cell differentiation
  • Treg phenotyping
  • Proliferation
  • Cytokine and chemokine release

In partnership with Axis Bio, we expand immune-oncology studies with syngeneic models and advanced immune profiling (flow cytometry, FACS, cytokine multiplexing, IHC).

Learn more about our

Immune Response Assays

In vivo Oncology models (in partnership with Axis Bio)

Axis Bio brings extensive expertise in validated in vivo oncology models, ensuring translational relevance and robust decision-making for oncology programs.

Xenograft models

  • Wide range of tumor types, validated against standard-of-care treatments
  • Implantation at flank or orthotopic sites
  • Client-specific cell line validation

Metastasis models

  • Studies with or without luciferase-expressing cells
  • Real-time bioluminescent imaging for tumor tracking

Syngeneic & humanized models

  • Advanced systems for immuno-oncology studies
  • PDX (patient-derived xenograft) models for enhanced clinical relevance

PK/PD studies

  • Compound exposure and biomarker analysis in tumor tissue
  • Optimization of dosing regimens for efficacy studies
  • INIVE (in vitro–in vivo extrapolation)

Advanced Capabilities for Novel Modalities

Our oncology platforms support cutting-edge therapeutic approaches, including:

  • Antibody-drug conjugates (ADCs)
  • Bispecific antibodies
  • CAR-T and other cell therapies
  • Gene therapies and protein degraders

To strengthen decision-making, Axis Bio provides in-depth mechanistic analysis such as deep immune phenotyping, cytokine arrays, histology, and transcriptomic integration. Combined with our ex vivo human skin capabilities, this creates a seamless workflow from in vitro validation to in vivo proof-of-concept

Partner with QIMA Life Sciences

With the integration of Axis Bio’s oncology expertise, QIMA Life Sciences offers a unique continuum of services spanning from cell-based assays and tumor microenvironment models to translational in vivo oncology studies.

Whether you are working on small molecules, biologics, or advanced modalities, our comprehensive solutions help you generate robust, decision-driving data across the entire oncology R&D pipeline.

Contact us today to learn how our oncology assays and models can accelerate your drug discovery and development programs.

Do you have a project requiring oncology expertise?
Let’s discuss today!

CONTACT US

Hello! How can we help you?

It takes less than a minute to ask us your question.

We will get back to you shortly!

(Required)
Keep up with what's happening in QIMA Life Sciences?(Required)
Terms of Services(Required)
This field is for validation purposes and should be left unchanged.